Calcitriol is indicated for the management of:
Calcitriol is the biologically active form of vitamin D3, produced in the kidneys from its precursor 25-hydroxycholecalciferol. It enhances intestinal absorption of calcium and plays a vital role in maintaining calcium balance and proper bone mineralization. It also stimulates osteoblastic activity, contributing to healthy skeletal function.
The optimal daily dose of Calcitriol capsule must be carefully determined for each patient on the basis of serum calcium level.
In Post-menopausal Osteoporosis: The recommended dose of Calcitriol capsule is 0.25 mcg twice daily.
In Renal Osteodystrophy (dialysis patients): The initial daily dose is 0.25 mcg of Calcitriol capsule. In patients with normal or only slightly reduced calcium levels, doses of 0.25 mcg every other day are sufficient.
In Hypoparathyroidism and Rickets: The recommended initial dosage of Calcitriol capsule is 0.25 mcg/day which given in the morning. If within 2-4 weeks satisfactory response is not observed by usual dose then dose may be increased at 2-4 weeks intervals.
The recommended intravenous initial dose of Calcitriol injection, depending on the severity of the hypocalcemia and/or secondary hyperparathyroidism, is 1 mcg (0.02 mcg/kg) to 2 mcg administered three times weekly, approximately every other day. Doses as small as 0.5 mcg and as large as 4 mcg three times weekly have been used as an initial dose. If a satisfactory response is not observed, the dose may be increased by 0.5 to 1 mcg at two to four week intervals.
Concurrent use of thiazide diuretics may increase the risk of hypercalcemia. Caution is required when calcitriol is used with digitalis, as elevated calcium levels may trigger cardiac arrhythmias. Magnesium-containing products (e.g., antacids) may lead to hypermagnesemia when used together.
Calcitriol is contraindicated in patients with known hypersensitivity to its components and in conditions associated with hypercalcemia.
Early adverse effects may include weakness, headache, drowsiness, nausea, vomiting, dry mouth, constipation, muscle and bone pain, and metallic taste. Late effects may include increased urination, excessive thirst, loss of appetite, weight loss, nocturia, conjunctivitis, pancreatitis, sensitivity to light, nasal discharge, itching, fever, decreased libido, elevated BUN, albuminuria, hypercholesterolemia, increased liver enzymes, ectopic calcification, hypertension, cardiac arrhythmias, and rarely psychosis. Mild pain at the injection site may occasionally occur.
There is no evidence that vitamin D is teratogenic in humans. Calcitriol may be used during pregnancy only if the benefits outweigh potential risks. Breastfeeding may be continued during treatment, but calcium levels of both mother and infant should be monitored.
Excessive doses of calcitriol may cause hypercalcemia and sometimes hypercalciuria. Use cautiously in patients receiving digitalis due to the risk of arrhythmias. Abrupt discontinuation may lead to rebound effects; gradual dose adjustment is recommended. If hypercalcemia develops, treatment should be stopped immediately. Vitamin D and its derivatives should be withheld during therapy. Non-aluminum phosphate binders may be used in dialysis patients. Chronic hypercalcemia may result in vascular and soft tissue calcification.
For secondary hyperparathyroidism in moderate to severe chronic renal failure (pre-dialysis):
Excess intake may lead to hypercalcemia, hypercalciuria, and hyperphosphatemia. Management includes stopping calcitriol, reducing calcium intake, and discontinuing calcium supplements.
Vitamin in bone formation, Vitamin-D preparations
Store in a dry place, protected from light and heat. Keep out of reach of children.
What is Calcitriol for?
What does Calcitriol do?
What are the side effects of Calcitriol?
What happens if you take too much Calcitriol?
Can Calcitriol be taken during pregnancy?
